Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab,
gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative
breast cancer.
The main questions it aims to answer are:
- to evaluate the anti-cancer efficacy (assess how well it works)
- to evaluate the safety and tolerability (how well the body can handle the treatment) of
this combination of anti-cancer therapy